Skip to main content
logo
IGM Biosciences, Inc. (IGMS)
Au 14, 2025 - IGMS was delisted (reason: acquired by Concentra Biosciences)
1.270
-0.030 (-2.31%)
Inactive · Last trade price on Aug 13, 2025

IGM Biosciences Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingJun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
145.052.682.131.07--
Revenue Growth
4882.82%25.77%99.25%---
Gross Profit
-5.49-152.51-211.66-178.22-127.03-65.03
Operating Income
10.26-194.22-261.64-227.96-165.32-83.28
Net Income
-53.39-195.8-246.42-221.1-165.16-81.36
Earnings Per Share
-0.88-3.24-4.71-5.32-4.93-2.65
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingJun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cash & Investments
104.31183.79337.68427.16229.54366.27
Total Debt
-45.1940.5141.1728.7612.24
Net Cash (Debt)
104.31138.6297.17385.99200.78354.03
Net Cash Growth
-51.93%-53.36%-23.01%92.24%-43.29%68.66%
Net Cash Per Share
1.712.295.689.296.0011.51

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingJun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Cash Flow
-156.51-153-192.23-5.85-124.98-67.88
Capital Expenditures
-2.19-5.85-12.38-10.21-13.24-17.5
Free Cash Flow
-158.7-158.85-204.61-16.06-138.23-85.38
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingJun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Margin
7.07%-7249.61%-12283.33%-21324.23%--
Pretax Margin
-36.80%-7308.51%-11537.00%-20683.07%--
Profit Margin
-36.80%-7308.51%-11568.83%-20683.07%--
FCF Margin
-109.41%-5929.38%-9606.20%-1502.24%--

Valuation
Chart
Fiscal YearCurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingJul '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
PS Ratio
-135.62227.82681.46--